Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared to the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully elucidated.
INTRODUCTION
Anthracyclines are widely used in the treatment of childhood cancer.(1) However, the use of anthracyclines is limited by their strong dose-dependent association with late-onset congestive heart failure (CHF).(1) Outcome of patients with anthracycline-related CHF is poor with 5-year mortality rates exceeding 50%.(1, 2) Anthracycline-related cardiotoxicity is mediated in part by direct myocardial injury due to formation of free radicals or toxic alcohol metabolites, disruption of myocyte fatty acid oxidation, or by topoisomerase-II-directed disruption of the myocyte mitochondrial genome. (1, 3) However, the exact mechanism of anthracycline-induced cardiotoxicity at the cellular level has not been completely elucidated.
Metabolomics refers to the comprehensive profiling of small-molecule metabolites found in biological specimens. The metabolome could represent the cumulative end product of gene expression, environmental factors or complex multi-faceted interactions between them.
Importantly, metabolomic analysis has the potential to elucidate molecular pathways involved in the pathogenesis of disease states such as anthracycline-related CHF and help identify druggable targets. In a recent study (4) of patients with primary dilated cardiomyopathy (DCM), decreased levels of plasma steroid metabolites, glutamine, histidine, threonine, and increased levels of lipid β-oxidation products were associated with disease severity. Importantly, clinical response to anti-congestive treatment such as furosemide and angiotensin-1 converting enzyme inhibitors corresponded with improvement in plasma metabolites such as glutamine, threonine, and steroid metabolites. These findings informed subsequent studies evaluating 
MATERIALS AND METHODS

Patient eligibility and recruitment
Childhood cancer survivors were recruited between October 2010 and September 2012 from the City of Hope or the Children's Hospital Los Angeles Childhood Cancer Survivorship Clinics.
Eligibility criteria included: 1) cancer diagnosis prior to 22 years of age, irrespective of current age; 2) two or more years after completion of cancer treatment; and 3) receipt of anthracycline chemotherapy. In order to ensure heterogeneity of anthracycline exposure, survivors at high risk (HR: cumulative anthracycline dose ≥300mg/m²) and low risk (LR: 1-299mg/m²) of developing CHF per the Children's Oncology Group Long Term Follow-up Guidelines(6) were targeted for recruitment. Furthermore, in order to enrich the cohort for those with cardiac dysfunction, patient recruitment disproportionately (2:1) targeted HR survivors over those who were LR. We excluded survivors who were actively being treated for cardiomyopathy, as pharmacologic therapy could possibly alter metabolomic profile. The study was approved by the respective institutional review boards. All study participants or their parents/ legal guardians provided informed consent.
Cardiac evaluation
Study participants underwent a detailed physical examination by their healthcare provider within the respective Survivorship Clinics, with special attention to signs and symptoms of CHF. Simpson biplane method.(7) LV end-systolic wall stress (ESWS) was calculated using the formula (1.35 x MAP x LVESD)/ ((4 x LVPWS) (1+LVPWS/LVESD)), (8, 9) where MAP is the mean arterial pressure as obtained by Dinamap blood pressure machine, LVESD is the LV chamber diameter in systole, and LVPWS is LV wall thickness in systole. A digitized and anonymized copy of each echocardiogram was sent to the study core cardiology laboratory (University of Michigan, Ann Arbor, MI) for a reading by the study cardiologist (SG) who was blinded to the risk status of the study participant. compound in each sample were used for statistical analysis (appendix). The dataset used for the current study included all detectable compounds of known identity (named biochemicals) that met established acceptance criteria for instrument and process variability; the final dataset included a total of 354 named biochemicals (appendix).
Clinical data collection
Self-reported questionnaires were used to obtain baseline demographics data, and medical record review allowed abstraction of the following information: date of diagnosis, type of cancer, stage of disease (if applicable), cumulative dose of anthracycline exposure and receipt of chestdirected radiation therapy. Lifetime cumulative anthracycline dose was calculated by multiplying the total dose of each anthracycline (doxorubicin, daunorubicin, epirubicin, idarubicin, and mitoxantrone) by a factor that reflects the cardiotoxic potential of each drug and then summing the products of the converted anthracyclines.(14)
Statistical analysis
Clinical characteristics of individuals with and without cardiac dysfunction: categorical variables were compared using Χ 2 tests, and continuous variables were compared using independent two-sample t-tests. Data were analyzed using SPSS Version 18.0 (IBM, Armonk, NY). All statistical tests were 2-sided, and P<0.05 were considered statistically significant.
Metabolomic analyses: Data for each compound were normalized using the median values for each run (appendix). This minimizes inter-day instrument gain drift, but does not interfere with intra-day sample variability. Welch's two-sample t-test was performed on the log-transformed data. To account for multiple comparisons, FDR method was used; (15) 
RESULTS
One hundred and fifty-two individuals were approached for participation in the study and 150 participated (HR: n=100; LR: n=50). One individual refused participation, and 1 did not complete the full battery of echocardiographic and blood testing (participation rate: 98.6%).
The salient characteristics of cancer survivors are presented in Table 1 . Median time from cancer diagnosis to study participation was 12.4 years (range 2.6 to 37.9 years), and 63%
were treated for a hematologic malignancy at a median age of 10.6 years (range 0.4 to 21.9 years). Median EF of study participants was 60% (range 50-85%), and none had clinical and are unavailable for energy production. (17, 19) In patients with a past history of myocardial infarction, administration of L-carnitine has been shown to lead to attenuation of left ventricular dilation, prevent LV remodeling, and is associated with a lower incidence of chronic heart failure and cardiac death. (20) These beneficial effects are thought to be due to the resumption of normal oxidative metabolism and restoration of myocardial energy reserves. 16, 17 Previous studies suggest that anthracyclines may exert at least part of their cardiotoxicity by inhibiting LCFA oxidation in the heart. It is important to note that the current study utilized a cross-sectional design. As a result, we are not able to state whether the cardiac dysfunction was due to pre-existing anthracyclinemediated carnitine depletion. In addition, we cannot exclude unrelated causes of carnitine deficiency such as differences in dietary intake or gastrointestinal absorption that may account for our findings. These limitations notwithstanding, the current study provides data to support a biologically plausible mechanism for cardiac dysfunction occurring years following completion of cardiotoxic therapy. Future longitudinal studies will need to evaluate whether carnitine depletion occurs during anthracycline administration, is sustained after completion of cancer therapy, and 
